Want to see PLSE full AI Analyst Report?
PLSE Stock Chart & Stats
$30.23
$2.56(8.47%)
At close: 4:00 PM EDT
$30.23
$2.56(8.47%)
Day’s Range― - ―
52-Week Range$12.56 - $50.90
Previous Close$32.94
Volume432.45K
Average Volume (3M)189.63K
Market Cap
$3.50B
Enterprise Value$1.82K
Total Cash (Recent Filing)$101.62M
Total Debt (Recent Filing)$6.77M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Nov 16, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding71,322,610
10 Day Avg. Volume222,519
30 Day Avg. Volume189,626
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$45.25Price Target Upside49.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.21
Revenue Forecast (FY)$2.38M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Safety EvidenceStrong feasibility outcomes support the potential durability and safety of nsPFA in atrial-fibrillation treatment. If replicated in pivotal studies, this evidence could improve physician adoption and strengthen the platform’s competitive position.
Efficient Procedure WorkflowHigh procedural throughput and a short learning curve can improve hospital and ambulatory-surgery-center economics. These workflow advantages may support repeat utilization, accelerate adoption and create a durable benefit versus more complex alternatives.
Broadening Clinical PipelineExpansion across cardiac, surgical and thyroid indications gives the nsPFA platform multiple paths to future commercialization. A broader pipeline can diversify clinical and revenue opportunities while allowing technology investments to support several products.
Bears Say
Very Limited Commercial RevenueThe small revenue base indicates commercialization remains at an early stage despite substantial clinical progress. Limited sales provide little internal funding and leave future performance highly dependent on successful regulatory approvals and broader procedure adoption.
Persistent Losses And Cash BurnHeavy operating cash consumption and deeply negative profitability show that growth currently requires significant external funding. Sustained clinical and commercialization spending could keep the company loss-making and constrain financial flexibility over the next several quarters.
Financing And Regulatory Execution RiskThe ATM provides liquidity but confirms continued reliance on equity markets, creating dilution risk while cash needs remain high. Separately, 12-month follow-up requirements make regulatory timing dependent on clinical execution, potentially delaying commercialization.
Pulse Biosciences News
PLSE FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $50.90 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $3.50B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is Nov 16, 2026 which is in 81 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on Aug 06, 2026. The company reported -$0.284 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.026.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.32.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 71,322,610 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.284 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went up 10.905%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in PLSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.25 (49.69% Upside)
$45.25 (49.69% Upside)
Blogger Sentiment
Bullish
PLSE Sentiment 80%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 12.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.90%
Trailing 12-Months
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
PLSE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, positive clinical momentum and operational progress: accelerated pivotal enrollment, compelling EU feasibility efficacy and safety data, procedural efficiency that suggests meaningful hospital economics, strengthened leadership, and a materially improved cash position following ATM proceeds. These positives are balanced by early-stage commercial revenue that remains small, rising operating expenses and widening losses driven by increased clinical investment, ongoing cash burn, and continued dependence on capital markets. Regulatory timing still depends on 12-month follow-up for earlier enrollees, creating a measurable timeline risk. On balance, the highlights — particularly the rapid enrollment, robust feasibility outcomes, and strengthened balance sheet — outweigh the lowlights.View all PLSE earnings summariesPLSE Stock 12 Month Forecast
Average Price Target
$45.25
▲(49.69% Upside)
Technical Analysis
Ownership Overview
70.86% Insiders
2.19% Mutual Funds
1.86% Other Institutional Investors
22.11% Public Companies and
Individual Investors